Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline

Stock Information for Mateon Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.